NauseaAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantPostoperative Nausea and VomitingVomitingAntiemeticsAntineoplastic AgentsCisplatinTreatment OutcomeCombined Modality TherapyDoxorubicinCyclophosphamideOndansetronDrug Administration ScheduleBreast NeoplasmsNeoadjuvant TherapyDisease-Free SurvivalPrimary PreventionSurvival AnalysisNeoplasmsEtoposideNeoplasm StagingSurvival RateLung NeoplasmsPrognosisCarboplatinMethotrexatePaclitaxelGranisetronVinblastineVomiting, AnticipatoryTaxoidsNeoplasm Recurrence, LocalDeoxycytidineFollow-Up StudiesInduction ChemotherapyProspective StudiesTime FactorsProchlorperazineAntimetabolites, AntineoplasticDrug Resistance, NeoplasmIfosfamideInfusions, IntravenousMetoclopramideMotion SicknessBleomycinClinical Trials as TopicDose-Response Relationship, DrugDouble-Blind MethodAnthracyclinesOrganoplatinum CompoundsNeutropeniaRisk FactorsSecondary PreventionCenters for Disease Control and Prevention (U.S.)Antineoplastic Agents, AlkylatingRandomized Controlled Trials as TopicSalvage TherapyNeoplasm MetastasisAcupressureCarcinoma, Non-Small-Cell LungSerotonin 5-HT3 Receptor AntagonistsOvarian NeoplasmsCytarabineAntineoplastic Agents, PhytogenicAdenocarcinomaDroperidolChemotherapy, Cancer, Regional PerfusionMorning SicknessRecurrenceColorectal NeoplasmsLeukopeniaCamptothecinRadiotherapyTesticular NeoplasmsLymphoma, Non-HodgkinTransplantation, AutologousRadiotherapy, AdjuvantAdministration, OralHodgkin DiseaseAntibiotics, AntineoplasticDrug EvaluationKaplan-Meier EstimateDacarbazineDexamethasoneGranulocyte Colony-Stimulating FactorBone NeoplasmsAccident PreventionBrain NeoplasmsNeoplasms, Germ Cell and EmbryonalLiver NeoplasmsPalliative CareInfusions, Intra-ArterialHyperemesis GravidarumDisease ProgressionStomach NeoplasmsUnited StatesPlatinum CompoundsCarmustineMitomycin